Global Male Infertility Treatment Market Growth (Status and Outlook) 2023-2029

Global Male Infertility Treatment Market Growth (Status and Outlook) 2023-2029

According to Word Health Organization, ‘Infertility is the inability of a sexually active, non-contraception couple to achieve pregnancy in one year’. About 15% of couples do not achieve pregnancy within 1year and seeking for infertility medical treatment. Less than 5% of world population is unwillingly childless. Approximately 90% of male infertility cases are seen mainly due to low sperm counts, and poor sperm quality. The remaining cases of male infertility can be caused by a number of factors including anatomical problems, hormonal imbalances, and genetic defects.

LPI (LP Information)' newest research report, the “Male Infertility Treatment Industry Forecast” looks at past sales and reviews total world Male Infertility Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Male Infertility Treatment sales for 2023 through 2029. With Male Infertility Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Male Infertility Treatment industry.

This Insight Report provides a comprehensive analysis of the global Male Infertility Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Male Infertility Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Male Infertility Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Male Infertility Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Male Infertility Treatment.

The global Male Infertility Treatment market size is projected to grow from US$ 1275.4 million in 2022 to US$ 2213.7 million in 2029; it is expected to grow at a CAGR of 8.2% from 2023 to 2029.

United States market for Male Infertility Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Male Infertility Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Male Infertility Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Male Infertility Treatment players cover Merck Serono, Aytu BioScience, Bayer, Cadila, Intas Pharma, Halotech DNA, SCSA diagnostics, Andrology Solutions and Livzon Pharmaceutical Group Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Male Infertility Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
DNA Fragmentation Technique
Oxidative Stress Analysis
Microscopic Examination
Sperm Agglutination
Computer Assisted Semen Analysis
Sperm Penetration Assay

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck Serono
Aytu BioScience
Bayer
Cadila
Intas Pharma
Halotech DNA
SCSA diagnostics
Andrology Solutions
Livzon Pharmaceutical Group Inc.
Zhejiang Xianju Pharmaceutical Co.,Ltd.
GeneScience Pharmaceuticals Co., Ltd.
Abeona Therapeutics Inc.
ASKA Pharmaceutical Co., Ltd.
Bristol Myers Squibb
Church & Dwight
Intas Biopharmaceuticals
Eli Lilly and Company

Please note: The report will take approximately 2 business days to prepare and deliver.